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I LITERATURE SECTION 
1. Introduction 
The gut and the brain are in a bidirectional communication known as the gut-brain axis (Collins 
et al., 2012). The gut-brain axis provides neuronal and humoral signals to orchestrate gut as 
well as brain function (Foster et al., 2017). Microbial community of the human gastrointestinal 
tract, known as the gut microbiota, can utilize the routes of gut-brain axis to alter host 
physiology (Holzer & Farzi, 2014). During recent years, the gut microbiota has been recognized 
as an important factor in various aspects of health and disease, including gut health, behavior, 
neurological diseases, autoimmune diseases, immune system maturation, and brain 
development (Forsythe et al., 2016; Sarkar & Banerjee, 2019; Wang & Wang, 2016).  
Multiple sclerosis (MS) is one of the aspects of health and disease that are 
proposed to be regulated by gut microbiota (Sarkar & Banerjee, 2019). MS is an inflammatory 
autoimmune disorder in which the immune system damages myelin and axons of the central 
nervous system (CNS), leading to neurodegeneration and severe disability (Dendrou et al., 
2015, Legroux & Arbour, 2015; Reich et al., 2018). Incidence of MS has increased worldwide 
(Browne et al., 2014; Compston & Coles, 2002; Wallin et al., 2019), being the most common 
cause of neurologic disability within young adults (Orton et al., 2006).  
  So far, the role of gut microbiota in MS has majorly been studied with experimental 
autoimmune encephalomyelitis (EAE), a murine model of MS. Mice grown in germ-free 
conditions do not develop EAE, but colonization with microbes triggers the condition (Berer et 
al., 2011; Lee et al., 2011). Patients with MS have altered gut microbiota composition compared 
to healthy controls (Chen et al., 2016; Jangi et al., 2016; Miyake et al., 2015). Chance that EAE 
susceptible mice will develop the disease is higher when they are colonized with gut microbes 
derived from MS patients compared to healthy controls (Berer et al., 2017). 
 One possible mechanism how the gut microbiota can modulate immune system 
(Fábrega et al., 2016), autoimmunity (Kimura et al., 2018), and other host related functions is 
the production of extracellular vesicles (EVs). EVs are spherical and bilayered structures that 
contain various biomolecules such as cytosolic proteins, membrane proteins, lipids, 
polysaccharides, and nucleic acids. (Molina-Tijeras et al., 2019), However, the role of gut 
microbial vesicles in health and disease is mostly unexplored. Therefore, the aim of this Pro 




different from healthy controls by examining characteristics and the protein load of microbial 
EVs. 
2. Review of the literature 
2.1 Multiple sclerosis 
Multiple sclerosis (MS), an inflammatory autoimmune disorder, is the most prevalent cause of 
nontraumatic neurologic disability among young adults, affecting more than 2 million people 
worldwide. Onset of the disease usually occurs between the age of 20 and 40, and is two-fold 
to three-fold more common among women than in men (Orton et al., 2006). Occurrence of MS 
is higher in North America, Europe, and Australia compared to Africa, Asia, and South 
America, but the number of people inflicted with the disease has increased in both developed 
and developing countries (Browne et al., 2014; Compston & Coles, 2002; Wallin et al., 2019).  
MS disease is characterized by inflammatory lesions that can appear anywhere in 
the CNS and the optic nerve due to infiltration of immune cells (Dendrou et al., 2015). Lesions 
can be imaged with magnetic resonance imaging (MRI) and seen as white areas in the CNS. 
These lesions contain activated peripheral immune cells, activated glia cells, and astrocytes, 
which are involved in myelin degeneration, axonal and neuronal damage, and oligodendrocyte 
death (Compston & Coles, 2002; Legroux & Arbour, 2015; Miyake & Yamamura, 2019; Reich 
et al., 2018).  
Patients with MS disease typically experience neurological disability episodes, 
which can last from days to weeks. Symptoms and their severity vary, depending on the location 
of lesions (Fig. 1.) (Compston & Coles, 2008; Kearney et al., 2015). Typical symptoms include 
loss of vision, double vision, impaired body balance and motility, limb weakness, sensory loss, 
and ataxia. At early disease stage, the neurons are mostly preserved but gradual neuroaxonal 
loss occurs as the disease progresses. Over time, usually in 10-20 years, the symptoms become 
persistent and lead to severe disability and cognitive impairment characterized by the loss of 
brain cells, deep grey matter and cortical demyelination, and ventricular enlargement (Dendrou 
et al., 2015; Legroux & Arbour, 2015; Reich et al., 2018). 
MS disease is divided into different sub-types. The most common type is relapse-
remitting MS (RRMS), that is characterized by periodic relapses and remissions. Relapses are 
neurologic disability episodes followed by remission, a partial recovery. Patients with RRMS 




in disability. Another subtype is defined as primary-progressive MS (PPMS) in which the 
disease progression is constant from the onset (Thompson et al., 2018).  
Figure 1. Symptoms of MS depend on the location of the lesion in the CNS and optic nerve. 
 
Both genes and the environment are involved in the onset of MS (Compston & 
Coles; 2002). Known risk factors for MS are smoking, lack of vitamin D, Epstein-Barr virus 
infection during adulthood, and obesity (Alfredsson & Olsson, 2019). Genetic risk for MS 
involves ~100 regions in the human genome, and in overall, the genetics count for ~30 % of 
the overall risk. Majority of these regions are associated with the genes involving immune 
function, such as human leukocyte antigen (HLA) alleles (Ascherio et al., 2012; Reich et al., 
2018). MS risk genes are also associated with other diseases involving immune dysfunction, 
such as ulcerative colitis, Crohn’s disease, primary biliary cirrhosis, celiac disease, rheumatoid 
arthritis, psoriasis, and autoimmune thyroid disease (Beecham et al., 2013). 
CNS is considered isolated or immunoprivileged from the access of peripheral 
immune system due to the function of blood-brain barrier (BBB). BBB is a physical barrier 
between blood and brain tissue (Barret et al., 2016), which protects neurons by limiting the 
access of peripheral components from the circulation (Banks et al., 2015). Breakage of the BBB 
is considered to be a preclinical sign of MS before the onset of neurological symptoms 




by pro-inflammatory T helper type (Th) 1 and Th17 cells (Kaskow & Baecher-Allan, 2018). 
MS manifests itself when self-reactive T cells migrate through the BBB and induce axonal 
damage and demyelination (Fletcher et al., 2010). Demyelination is orchestrated by 
macrophages, microglia, cytotoxic CD8+ cells (Dendrou et al., 2015; Lassmann, 2014), and  
antibody secreting B cells (Reich et al., 2018).  
Self-reactive T cells are usually eliminated by negative selection in the thymus 
(Kappler et al., 1987). Despite selection, part of the self-reactive cells escape into the periphery. 
However, self-reactive peripheral T-cells are not only present in people with autoimmune 
disease but are constantly generated among healthy individuals. People with no autoimmune 
disease are able to maintain unresponsiveness towards self-antigens, known as self-tolerance  
(Lohmann et al., 1996; Semana et al., 1999; Van Parijs & Abbas, 1998). Self-tolerance is 
mediated by T regulatory cells (Tregs) and absence of these cells has been shown to initiate 
autoimmune diseases (Sakaguchi et al., 1995). 
Two models, CNS-extrinsic and -intrinsic, exist to explain the pathogenesis of 
MS, since it is not known if the triggering action of MS occurs outside or inside the CNS. CNS-
extrinsic model, or peripheral model, involves activation of T-cells outside the CNS, that leads 
to infiltration of CNS with T cells along with activated B cells and monocytes. CNS-intrinsic 
model suggests that infiltration of lymphocytes is a secondary response to currently unknown 
factors that could occur in the CNS (Dendrou et al., 2015). Target antigens, that initiate MS 
episodes, are thought to be present only in the CNS, since it is the only place affected by 
infiltration (Thompson et al., 2018). 
Molecular mimicry and bystander activation are suggested to be possible CNS-
extrinsic mechanisms how microbial agents could induce MS. Molecular mimicry mechanism 
involves self-reactive T and B cells that recognise microbial peptides or other antigens, 
presented by antigen presenting cells, that share molecular similarities with the self-antigens 
expressed in the CNS. These cells, that have recognized mimicking bacterial antigen, could 
infiltrate the CNS. If cells re-recognize antigens expressed by the CNS, they can initiate 
neurological damage. Bystander activation mechanism suggests that activation of self-reactive 
T cell reaction is initiated by cooperation of microbial antigens and cytokines. Alternatively, 
release of self-antigens and inflammation promoting viral particles from virus-infected cells 




2.3 Gut microbiota 
Broad spectrum of microbes, termed as the gut microbiota, lives within the gastrointestinal tract 
of humans. While mainly consisting of bacteria, the human gut microbiota also harbors archaea, 
protists, yeasts, and viruses (Quigley, 2013). Estimated number of bacterial cells in the gut is 
38 trillion, a number that is close to the number of cells in the human body. While the mass of 
microbiota is approximately 0.2 kg (Sender et al., 2016), it has a gene reserve ~100-150 fold 
larger compared to human genome, providing functional potential to impact host physiology 
(Gill et al., 2006; Qin et al., 2010). Metabolic activity of the microbial community in the gut 
provides compounds that are beneficial to the host. Commonly known products include 
functional metabolites such as vitamin K, folic acid, short-chain fatty acids (SCFAs), and amino 
acids. Gut microbiota works as a barrier against pathogen colonization and promotes maturation 
and function of the immune system (Quigley, 2013). The role of microbiota in health and 
disease has been recognized as a potential factor, as the knowledge about the function of 
microbial community regarding the host well-being have increased over the last years (Quigley, 
2013, Sarkar & Banerjee. 2019). 
Establishment of gut colonization begins at birth when the infant is in first contact 
with maternal and environmental bacteria. Initial gut microbiota composition varies, depending 
whether the delivery is performed vaginally or by caesarean section (Dominguez-Bello et al., 
2010). Development of gut microbiota proceeds by breastfeeding, which provides a regular 
supply of bacteria, 8 x 104 - 8 x 106 bacteria cells per day (Heikkilä & Saris, 2003), to the infant 
gut (Fernández et al., 2013). Starting from the age of one, the gut microbiota of an infant 
converts to an adult-like composition when solid foods are introduced to the diet (Stark & Lee, 
1982). Adulthood microbiota is suggested to be stable (Zoetendal et al., 1998), while the 
composition of gut microbiota can be shaped by various factors including diet (David et al., 
2014), intake of antibiotics (Ochoa-Repáraz et al., 2009), environmental factors (Rothschild et 
al., 2018) such as hygiene level (Adlerberth et al., 1998), aging (Claesson et al., 2011), function 
of immune system (Hooper & MacPherson, 2010), and stress (Karl et al., 2017).  
Most of the gut bacteria are anaerobes with a relation of 100 to 1000:1 compared 
to aerobic bacteria (Quigley, 2013). Mature human gut microbiota is dominated by a few 
bacteria phylum. Major contributors are Bacteroidetes and Firmicutes, and minor contributors 
belong to Actinobacteria, Proteobacteria, and Verrucomicrobia (Arumugam et al., 2011, 
Lozupone et al., 2012; The Human Microbiome Project Consortium, 2012). Estimated number 




microbiota is suggested to involve ~40 partially stable species (Martínez et al., 2013). Part of 
the gut microbiota involves transient microbes that more or less travel through the 
gastrointestinal tract (Sears et al., 1950).  
Distribution of microbiota i.e. biogeography in the gastrointestinal tract varies, 
depending on the physiological properties of the gut at given region (Fig. 2). While providing 
variable microbial habitats, circumstances in the gut determine, which bacteria are able to 
flourish. Lactobacillaceae and Enterobacbacteriaceae dominate the small intestine. Due to 
harsh conditions in the small intestine caused by acidity, presence of oxygen, and antimicrobial 
agents, the resident microbes need to be fast growing and capable to compete with the host for 
the use of simple carbohydrates. Therefore, the number of microbes living in the small intestine 
is low compared to the lower parts of the intestine (Donaldson et al., 2015; Swidsinski et al., 
2005). 
Intestinal circumstances gradually grow more temperate and the bacterial load 
increases along the gut before reaching peak densities in the colon and cecum. In the colon, 
resident microbes use complex carbohydrates, compounds otherwise undigestable to the host, 
and mucus as an energy source. Transverse regions in the colon, such as outer and inner mucus 
and digested material, provide diverse habitats for bacterial growth. Microbes dominating the 
colon inner fold regions is composed by microbe families such as Lachnospiraceae and 
Ruminococcaceae. Outer colon mucus layer, or loose mucus, is inhabited by mucus-degrading 
bacteria including Bacteroides acidifaciens, Bacteroides fragilis, Bifidobacteriaceae, and 
Akkermansia muciniphila. Inner colon mucus, also known as attached mucus, is in close 
proximity of gut epithelial cell layer, and is inhabited by B. fragilis and Acinetobacter spp. 
Dominating microbial families, whom reside in the digested material, belong to 
Bacteroidaceae, Prevotellaceae, and Rikenellaceae. (Donaldson et al., 2015; Frank et al., 2007, 
Swidsinski et al., 2005; Thursby & Juge, 2017). 
Gut microbiota is suggested to have a role in neurodegenerative diseases due to 
its ability to affect CNS function via bidirectional communication system known as the 
microbiota-gut-brain axis (Fig. 3) (Sarkar & Banerjee, 2019). Communication routes of the 
microbiota-gut-brain axis include immune system, vagus nerve, enteric nervous system, gut 
hormones, and hypothalamus-pituitary-adrenal axis. Gut microbiota produce functional 
metabolites such as SCFAs, and tryptophan-derived compounds (Kelly et al., 2017; Collins et 




astrocytes (Erny et al., 2015) and microglia (Rothhammer et al., 2016). Free fatty acid receptors 
2 and 3 that recognize SCFAs are also present in the colon enteroendocrine cells (Lund et al., 
2018), ganglions of sympathetic (Kimura et al., 2011), and parasympathetic  nervous system, 
including the vagus nerve (Nøhr et al., 2015). 
Gut microbiota has been shown to affect BBB integrity by influencing the 
expression of claudin-5 and occludin, proteins that regulate permeability of BBB tight 
junctions. Bacteria that produce SCFAs, such as butyrate, propionate, and acetate promote BBB 
integrity (Braniste et al., 2014). Additionally, butyrate producing bacteria have been reported 
to have neuroprotective properties in a mouse model of vascular dementia (Liu et al., 2015).  
Propionate doesn’t affect the expression of tight junction proteins, but protects BBB from 
lipopolysaccharide (LPS) induced inflammation by reducing oxidative stress (Hoyles et al., 
2018). LPS is a compound found on the outer membrane of gram-negative bacteria, and is 
known to reduce BBB integrity (Banks et al., 2015). Propionate promotes the function of 
nuclear factor-erythroid 2 p45 related factor 2 (NRF2) (Hoyles et al., 2018), that regulates the 
expression of genes involved in the protection of cells from oxidative stress (Dinkova-Kostova 
et al., 2018). NRF2 is suggested to also have a protective role in neurogenerative diseases such 
as Parkinson’s disease (Williamson et al., 2012) and Alzheimer’s disease (Fragoulis et al., 
2017). In other words, disruptions in BBB integrity can potentially promote development of 
neurodegenerative diseases (Sweeney et al., 2018). Additionally with previously mentioned 
MS disease, breakage of BBB has been suggested to be an early biomarker in cognitive 
dysfunction (Nation et al., 2019), and disruption of BBB is also associated with Parkinson’s 













Figure 2. Gut biogeography of the small intestine and colon. Low pH, oxygen, antimicrobial peptides (AMPs) 
released by Paneth cells, and secreted immunoglobulin A (SIgA) limit bacterial growth in the small intestine. 
Goblet cells produce mucus that prevents the access of bacteria into host cells both in small intestine and colon. 
Bacterial diversity increases along the intestine where circumstances grow more favorable for bacterial survival. 
Outer mucus layer of the colon provides a growth habitat for various mucin-degrading bacteria whereas inner 




Figure 3. Communication routes of the microbiota-gut-brain axis. Metabolites produced by the gut microbiota 
influence function of the immune system e.g. by affecting cytokine production. Gut epithelial cells have a 
repertoire of receptors that recognize microbial products, which affects gut hormone release. Microbial products 
can pass gut barrier and influence vagus nerve and enteric nervous system. Products that enter circulation travel 
through the body and are even capable to enter the brain. Hypothalamus-pituitary-adrenal axis is a suggested route 
how the microbiota alters stress-related responses.  
 




2.4 The role of gut microbiota in experimental autoimmune encephalomyelitis 
Gut microbiota influences the function of the host immune system not only in the gut area but 
also in the periphery and in the CNS. The effect of gut microbiota can be both inflammatory 
and anti-inflammatory. Gut microbiota has been shown to promote innate immune system 
function against pathogens by releasing peptidoglycan into host circulation. (Clarke et al., 
2010). Clostridium clusters IV and XIVa are associated with accumulation of Foxp3+ Tregs, 
cells that promote anti-inflammatory response, in the mice colon (Atarashi et al., 2011). 
Segmented filamentous bacteria (SFB) can increase the amount of Th17 cells in mice lamina 
propria, leading to increased production of pro-inflammatory interleukin (IL)-17 and IL-21 
from Th-17 cells. (Ivanov et al., 2009). SCFAs have been shown to induce colonic Treg cell 
function and proliferation (Furusawa et al., 2013; Smith et al., 2013), as well as regulate 
microglia maturation and function in the CNS (Erny et al., 2015). Gut bacteria can produce 
tryptophan-derived metabolites that function as a aryl hydrocarbon receptor antagonists to 
suppress neuroinflammation in the CNS (Rothhammer et al., 2016).  
  The role of gut microbiota in the pathogenesis of MS can be studied with mice 
and rats that will develop a condition called experimental autoimmune encephalomyelitis 
(EAE). EAE is a Th-1/Th-17 cell mediated demyelinating disease of CNS and is commonly 
used as a MS model. EAE is induced by challenging the immune system with myelin proteins 
or with other myelin protein corresponding peptides in complete Freund’s adjuvant, leading to 
autoimmune inflammation. Alternatively, induction can be done with activated neuroantigen-
specific T cells via adoptive cell transfer. EAE can also occur spontaneously with certain 
transgenic mouse strains. EAE induced mice will develop progressive hind-limb paralysis. 
Depending on the used mouse strain, EAE can be chronic or take a relapse-remitting course. 
Severity of the EAE i.e. the clinical score is evaluated by using a five-point system (Table I). 
Scoring is used to monitor clinal stages of the disease such as remissions and relapses (Miller 
et al., 2007).  
In the onset of EAE peripheral T cells migrate across the BBB to CNS and cause 
inflammatory response (Furtado et al., 2008). Th1 cells infiltrate CNS first and induce 
inflammation by recruiting Th17 cells (O'Connor et al., 2008). Release of chemokines and pro-
inflammatory cytokines including interferon gamma (INF-γ), tumor necrosis factor (TNF) and 
IL-17 damages CNS and promotes activation as well as chemoattraction of monocytes and 




      Table I. Evaluation of EAE severity in mice. 







Normal, no signs of disease 
Limp tail or hind limb weakness 
Limp tail and hind limb weakness 
Partial hind limb paralysis 
Complete hind limb paralysis 
Moribund 
 
Mice that would otherwise develop spontaneous EAE at the age of 3-5 months, 
stay healthy through their life when grown in germ-free conditions. However, colonization of 
germ-free mice with microbes returns the susceptibility to EAE and triggers autoimmunity. 
While EAE in germ-free mice can be induced, they show delayed disease onset, lower disease 
severity compared to specific pathogen-free (SPF)-mice, have increased amount of Tregs, and 
lower levels of pro-inflammatory cytokines IFN-γ, IL-17A in the intestine and spinal cord. 
Reduction in the amount of Th17 cells in germ-free mice lamina propria and Peyer’s patches is 
also observed upon EAE induction (Berer et al., 2011; Lee et al., 2011). On the other hand, 
self-reactive Th17 cells were shown to accumulate in the intestine of spontaneous EAE resistant 
mice. Reduced amounts of these Th17 cells were observed in the periphery, suggesting the role 
of gut as a keeper of self-reactive immune cells (Berer et al., 2014). 
 During adolescence/early adulthood (5-10 weeks), the disturbance of the gut 
microbiota, known as gut dysbiosis, have been shown to promote EAE pathogenesis by 
impairing self-tolerance in mice (Yadav et al., 2017). Whether the EAE establishes as chronic 
progressing or relapse-remitting, is suggested to be regulated by the gut microbiota (Gandy et 
al., 2019). Risk for EAE is higher when spontaneous EAE susceptible mice are colonized with 
gut microbes derived from MS patients (Berer et al., 2017). Similarly, colonization of germ-
free mice with MS patient derived microbiota, before EAE induction, resulted more severe 
disease compared to colonization with microbiota from healthy controls. (Cekanaviciute et al., 
2017). Mice treated with MS patient derived microbiota showed reduced production of anti-
inflammatory IL-10 from splenocytes (Berer et al., 2017) and mesenteric lymph nodes 
(Cekanaviciute et al., 2017). Interestingly, oral fecal administration from EAE mice during 
peak-disease, i.e. when clinical score of EAE is at its highest, could reduce EAE severity when 




albino oxford rats, that are highly resistant to EAE, could also ameliorate the disease in dark 
agouti rats (Stanisavljević et al., 2018). 
Use of antibiotics have been shown to alter EAE. Perturbation of gut microbiota 
with orally administered antibiotics prior to EAE induction has been shown to impair EAE 
development and reduce disease severity in mice. Reduced EAE severity is associated with 
decreased production of pro-inflammatory cytokines and, on the other hand, increased 
production of anti-inflammatory IL-10 (Gödel et al., 2020; Ochoa-Repáraz et al., 2009; Seifert 
et al., 2018; Yokote et al., 2008; Zeraati et al., 2019). Opposite results are observed in rats when 
antibiotics are orally administered after birth (Stanisavljević et al., 2018). Early life antibiotic 
treatment exacerbated EAE severity in rats when the disease was induced several weeks after 
the antibiotics were excluded from the drinking water (Stanisavljević et al., 2019). Interestingly, 
antibiotic treatment didn’t affect EAE significantly if the disease was already manifested and 
ongoing (Gödel et al., 2020). 
Ameliorating effects on EAE have also been achieved with probiotics, that are 
administered prior/after EAE induction or/and during the ongoing disease (Abdurasulova et al., 
2017; Chen. et al., 2019; Consonni et al., 2018; Ezendam et al., 2008; He et al., 2019; Kwon 
et al., 2013; Lavasani et al., 2010; Libbey et al., 2018; Liu et al., 2019; Maassen et al., 1998; 
Mangalam et al., 2017; Ochoa-Repáraz et al., 2010; Rezende et al., 2012; Salehipour et al., 
2017; Takata et al., 2011), while no effect or increased EAE severity have also been reported 
(Baken et al., 2006; Ezendam & van Loveren, 2008; Ezendam et al., 2008; Kobayashi et al., 
2010; Maassen et al., 1998). Results of these studies are listed in Table II. 
Table II. Effect of probiotic administration on EAE. Continued on next pages. 













libitum in water for 





gavage on alternate 
days until the end 






Reduced EAE severity, reduced 
CNS infiltration by CD4+ T cells, 
decreased myelin 
oligodendrocyte glycoprotein-
reactive T-cell proliferation, 
decreased IFN-γ and TNF-α 
production, and increased IL-4, Il-
10 and transforming growth 











B. fragilis Mice were treated 
with antibiotics, 
followed by a 




EAE in SPF- 
mice. 
Reduced EAE severity. Increased 
levels of IFN-γ, IL-10, IL-12, 
GATA-3 and SMAD-3. 












ad libitum in water 
OR with daily 
gavage until the 





Reduced EAE severity, decreased 
CNS infiltration of mononuclear 
cells, reduced Il-17 production. 
Increased Il-10 expression. 





offered ad libitum 
in a medium.  
Administration was 
done for 4 days. 
Immunization was 





Reduced EAE severity and onset, 
reduced CNS inflammatory cell 
infiltration, absent white matter 
lesions, reduced production of 
IFN-γ and IL-17 and increased 
expression of IL-10. 
Rezende et 
al., 2012 




bifidum & S. 
thermophilus 
Probiotics were 
given via gavage. 
Administration 
started 3 weeks 
before EAE 
induction and 
continued until the 





Reduced EAE severity and 
incidence, decreased lymphocyte 
infiltration to CNS. Reduced 
production of IFN-γ, TNF-α and 
IL-17. Increased IL-10 
expression. 
Kwon et al., 
2013 
E. faecium L3 Probiotics were 
given via gavage. 
Administration 
started 2 days after 
disease induction 






Reduced EAE severity. Shift in 
gut microbiota composition. 
Abdurasulova 
et al., 2017 
P. histicola Probiotics were 
given via gavage. 
Administration 
started 7 days after 
disease induction 
and included 7 
doses on alternate 
days. 
Induced 
EAE in SPF- 
mice. 
EAE incidence reduced by 75%. 
Reduced CNS inflammation and 
demyelination. Decreased IFN-γ 
and IL-17 production. Increased 
Il-10 production. Reduced BBB 
and gut permeability. Decreased 
number of Th1 and Th17 cells in 
the CNS. Increased number of 
CD4+ CD25+ Tregs and 
tolerogenic dendritic cells. Shift 












L. plantarum A7, 
B. animalis PTCC 
1631 or a mixture 
of these. 
Probiotics were 
given via gavage. 
Administration 
started during the 
day of disease 
induction and 





Reduced EAE severity and 
delayed onset. Reduction was 
higher with probiotic mixture. 
Reduced CNS infiltration and 
demyelination. Reduced self-
reactive T-cell proliferation, and 
Th1/Th17 polarization. Increased 
number of Foxp3 Tregs. Reduced 
levels of IFN-γ, IL-17 and IL-6. 
Increased levels of IL-4, IL-10 
and TGF-β.  
Salehipour et 
al., 2017 
L. crispatus LMG 
P-23257 + L. 
rhamnosus ATCC 
53103 / B. 
animalis subsp. 





given via gavage. 
Administration 
started one week 
before disease 
induction (5 doses) 
and continued for 







Reduced EAE severity. 
Decreased CNS infiltration by T 
cells. Decreased astrocytosis. 
Reduced levels of IFN-γ, IL-17 
and TNF-α (bifidobacterial 
treated rats). Increased levels of 
IL-6 and TGF-β in spinal cord.  
Consonni et 
al., 2018 
L. paracasei Probiotics were 
given via gavage. 
Administration 
started 14 days 
prior EAE 
induction and 






Reduced EAE severity, incidence 
and weight loss. 
Libbey et al., 
2018 
C. butyricum Probiotics were 
given via gavage. 
Administration was 
done 3 weeks prior 
induction. 
Induced 
EAE in SPF- 
mice. 
Reduced EAE severity. 
Decreased CNS lymphocyte 
infiltration, and demyelination. 
Shifted gut microbiota 
composition. Decreased number 
of Th17 and Th1 cells. Increased 
proportion of Foxp3 Tregs. 
Chen et al., 
2019 
A. muciniphila Probiotics were 




and lasted for 7 
days. 
Induced 
EAE in SPF- 
mice. 
Reduced EAE severity. Reduced 
demyelination and axonal loss. 
Increased number of myelin 
oligodendrocyte glycoprotein-
specific Foxp3+ Tregs and total 
Tregs.  
Liu et al., 
2019 
L. reuteri DSM 
17938 
Probiotics were 
given via gavage. 
Administration 
started during the 
day of disease 
induction and 
continued for 20 
days. 
Induced 
EAE in SPF- 
mice. 
Delayed onset and reduced EAE 
severity. Reduced CNS 
infiltration by inflammatory cells. 
Decreased number of CD3+ T 
cells, Th17 cells and Th1 cells. 
Reduced levels of IFN-γ and IL-
17. 










L. reuteri ML1, 
L.casei 393, 
L.plantarum 
NCIB 8826, L. 
murines CNRZ 
Probiotics were 
given via gavage. 
5 doses on alternate 






 L. reuteri increased EAE 
severity, L.casei and L.plantarum 
had no or little effect on EAE 




L. casei Shirota Probiotics were 
given via gavage. 
Administration 
started 8 days prior 
EAE induction and 
continued for 28 
days until the end 





Increased EAE severity. Baken et al., 
2006 
B. animalis Probiotics were 
given via gavage. 
Administration 
started 5 weeks 
before induction 
and continued for 
27 days until the 





Shortened duration of clinical 
symptoms. Slight but 




L. casei Shirota Probiotics were 
given via gavage. 
Administration 
started 5 weeks 
before induction 
and continued for 
27 days until the 






Increased disease duration in 
female rats. No significant 




L. casei Shirota, 
B. breve Yakult 
Probiotics were 
given via gavage. 
Administration 
started one week 
before induction 
and continued 28 
days until the end 
of the experiment. 
OR 
Administration 
started 5 weeks 
before induction 
and continued for 4 
weeks until the end 





Slight but unsignificant reduction 
in EAE severity with L. casei 
Shirota. C. breve Yakult had no 




Majority of the listed studies report that probiotic administration ameliorates EAE 
and is associated with reduced inflammatory (Th-17/Th-1 cells, IFN-γ, TNF-α and IL-17) and 
increased regulatory response (Tregs, IL-10). However, mechanisms how gut microbiota is able 




polysaccharide A (PSA) of Bacteroides fragilis (Ochoa-Repáraz et al., 2010; Wang et al., 
2014), SCFAs (Melbye et al., 2019), and tryptophan metabolites (Rothhammer et al., 2018; 
Sonner et al., 2019) have been suggested to play a role in EAE regulation.  
Interestingly, one EAE ameliorating mechanism is suggested to involve host 
derived fecal micro-RNA miR-30d, that is enriched in EAE mice as well as untreated MS 
patients. Fecal transfer from EAE mice during peak-disease ameliorated the disease in EAE 
induced mice. Similar results were achieved with feces-derived RNA and synthetic miR-30d. 
MiR-30d, upregulated by colon dendritic cells (DCs), was found to expanse Akkermansia 
muciniphila growth by inducing β-galactosidase production. A. muciniphila was shown to affect 
cytokine release of DCs by inducing the expression of transforming growth factor β (TGF-β) 
and decreasing the expression IL-6 and IL-1β. This in turn, promoted naive CD4+ T cell 
differentiation to anti-inflammatory Foxp3+ Tregs (Liu et al., 2019). Additionally, increased 
amount of A. muciniphila have also been reported among MS patients (Berer et al., 2017; 
Cekanaviciute et al., 2017; Jangi et al., 2016; Tremlett et al., 2016). 
Probiotics administration (Abdurasulova et al., 2017; Chen et al., 2019; He et al., 
2019) and changes with diet (Cignarella et al., 2018; Libbey et al., 2018) are associated with 
both changes in gut microbiota composition and EAE amelioration. Administration of 
Lactobacillus reuteri to EAE mice increased the proportion of Bacteroides and decreased the 
abundance of Proteobacteria and Deferribacteres. Alterations in gut microbiota composition 
were also associated with EAE severity scores. 16 genera, such as Clostridium,  Anaeroplasma, 
Ruminococcus, and Rikenellaceae, were associated with more severe disease whereas 17 
genera, including  Bifidobacterium, Prevotella, Lactobacillus, and S24-7 were involved with 
reduced EAE severity (He et al., 2019). Administration of Clostridium butyricum was shown 
to ameliorate EAE and affect the abundancy and diversity of the microbiota. C. butyricum 
increased Bacteroides/Firmicutes ratio and the amount of Prevotella. Decrease in the amount 
of Desulfovibroneceae and Ruminococcus was also observed (Chen. et al., 2019). 
Administration of  Enterococcus faecium also reduced EAE severity and was associated with 
reduction in Bifidobacterium, E.coli, and Bacteroides fragilis, and with increased levels of 
Faecalibacterium prausnitzii (Abdurasulova et al., 2017). Studies regarding changes in diet 
showed that increased abundance of Lactobacillaceae was observed together with reduced EAE 
severity in mice, that received Teklad sterilizable rodent diet compared to mice receiving 




was also shown to reduce EAE severity and increase the abundance of Bacteroidaceae, 
Lactobacillaceae, and Prevotellaceae (Cignarella et al., 2018). 
2.5 Gut microbiota in multiple sclerosis 
Studies including MS patients, regarding the role of gut microbiota, have been limited so far. 
Alterations in gut microbiota composition in MS patients compared to healthy controls have 
been reported (Chen et al., 2016; Jangi et al., 2016; Miyake et al., 2015). Preliminary results 
also indicate that the gut microbiota composition affects the relapse risk in pediatric RRMS 
patients (Tremlett et al., 2016). Diversity of the gut microbiota seems to be similar between MS 
patients and healthy controls (Mirza et al., 2020; Reynders et al., 2020). However, there is 
microbial heterogeneity between different MS subtypes and differences in microbial taxa 
(Reynders et al., 2020). MS patients seem to have lover amount of Prevotella, Bacteroides 
coprophilus, and Bacteroides fragilis, and higher amounts of archaea Methanobrevibacter, 
Akkermansia muciniphila and Faecalibacterium prausnitzii (Mirza et al., 2020). One case-
study reported the presence of epsilon toxin producing type B Clostridium perfringens in MS 
patients. Epsilon toxin can enter host circulation and travel to the brain where the toxin initiates 
symptoms typical to MS disease (Rumah et al., 2013). Few studies are published so far 
regarding the effect of probiotic intake in MS patients. 12 week long intake of probiotic mixture 
containing Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum and 
Lactobacillus fermentum had favorable effect on disability score and mental health of MS 
patients (Kouchaki et al., 2017), and increased expression of IL-8 and TNF-α (Tamtaji et al., 
2017).  Anti-inflammatory response and reduced expression of MS related risk alleles were 
observed with MS patients who were given a probiotic mixture containing Lactobacillus, 
Bifidobacterium, and Streptococcus for 2 months (Tankou et al., 2018). 
2.6 Microbial extracellular vesicles – multifunctional voyagers 
Eukaryotes and prokaryotes alike, including the gut microbiota, release extracellular vesicles 
(EVs) (Fig. 4.) into their environment. EVs are a heterogenous group of spherical bilayered 
structures that vary in size and origin (Molina-Tijeras et al., 2019). Role of microbial EVs is 
suggested to be involved in bacterial survival, nutrient sensing, transportation, eradication of 
competing bacteria, virulence against the host, and host immune modulation (Macia et al., 
2020). Interestingly, bacterial EVs are also proposed to be one mechanism how gut microbiota 
is able to communicate with the host organism (Fábrega et al., 2016; Kimura et al., 2018; 




Figure 4. Structure and components of bacterial EV. LPS: lipopolysaccharide (only in gram-negative bacteria 
EVs). 
Microbial EVs contain a cargo that resembles contents of the parental bacteria 
(Dorward et al., 1989; Kadurugamuwa & Beveridge, 1995; Kolling & Matthews, 1999; Molina-
Tijeras et al., 2019; Patrick et al., 1996), though bacteria are also able to selectively sort cargo 
into EVs (Haurat et al., 2011). Biomolecules present in EVs include cytosolic and membrane 
proteins, lipids, polysaccharides, LPS, toxins, and nucleic acids, such as linear and circular 
DNA, and RNA (Dorward et al., 1989; Kadurugamuwa & Beveridge, 1995; Kolling & 
Matthews, 1999; Molina-Tijeras et al., 2019; Patrick et al., 1996). 
EVs released by gram-negative bacteria are known as outer membrane vesicles 
(OMV), if EVs bled from the outer membrane of the bacterial cells. Other type of EV released 
by gram-negative bacteria is called outer-inner membrane vesicle (OIMV), which includes both 
inner membrane and outer membrane of the parental cell. EVs released by gram-positive 
bacteria are called bacterial membrane vesicles (BMV), which bled through the thick 
peptidoglycan wall  (Liu et al., 2018; Macia et al., 2020; Toyofuku et al., 2019). Size of 




Production of OMVs is a common feature among gram-negative bacteria (Kulp 
& Kuehn, 2010). However, biogenesis of OMVs is still largely unknown but is thought to 
involve several mechanisms including either blebbing or cell lysis (Fig. 5.) (Pathirana & 
Kaparakis-Liaskos, 2016; Toyofuku et al., 2019). One OMV blebbing mechanism is based on 
accumulation of phospholipids to the outer leaflet of outer membrane. This is due to reduced or 
deleted expression of genes vacJ and/or yrb, that express ATP-binding cassette (ABC) transport 
system (Roier et al., 2016). 
Outer membrane of gram-negative bacteria is asymmetric, having LPS at the outer 
leaflet and phospholipids at the inner leaflet. One function of ABC transporters is to traffic 
phospholipids out from the outer leaflet to prevent phospholipid accumulation (Malinverni & 
Silhavy, 2009). Iron limitation and possibly other environmental factors could downregulate 
vacJ and yrb, resulting increased accumulation of phospholipids to outer leaflet and induced 
OMV production. VacJ and yrb gene deletion increases OMV production of distinct bacteria 
species, leaving a suggestion that such OMV production mechanism is potentially conserved 
among gram-negative bacteria (Roier et al., 2016). 
Other suggested OMV production mechanism, known as bilayer-couple model, is 
based on the function of Pseudomonas quinolone signal (PQS). PQS is a hydrophobic molecule 
(Pesci et al., 1999) that functions as a signal molecule for bacterial communication and is 
required for vesicle formation in Pseudomonas aeruginosa (Mashburn & Whiteley, 2005). 
Similarly with previous model, it is suggested that accumulation of PQS to outer leaflet and 
interaction with LPS induces OMV formation. PQS is suggested to bind LPS lipid A, which 
results low-rate asymmetric flip-flop action, leading to outer leaflet expansion and OMV 
formation (Schertzer & Whiteley, 2012).  
Another OMV secretion mechanism involves turgor pressure against the outer 
membrane caused by the accumulation of peptidoglycan, misfolded proteins or LPS into 
bacterial periplasmic space. Turgor pressure could bend the outer membrane, leading to OMV 
production (Haurat et al., 2015; McBroom & Kuehn, 2007). OMV production can be also 
altered by changes in the outer membrane structure, presumably in the structure and metabolism 




Figure 5. Proposed EV biogenesis mechanisms in gram-negative (A-D, F) and gram-positive bacteria (E). A: 
Excess accumulation of phospholipids to the outer leaflet of outer membrane of gram-negative bacteria induces 
EV formation. B: Accumulation of Pseudomonas quinolone signal (PQS) to outer leaflet of outer membrane and 
interaction with LPS induces EV formation in P. aeruginosa. C: Misfolded proteins accumulate into the 
periplasmic space of gram-negative bacteria, inflicting turgor pressure against outer membrane, which leads to EV 
formation. D: Modulation of peptidoglycan-lipoprotein-outer membrane structures induce EV formation. E: 
Opening of thick peptidoglycan wall in gram-positive bacteria causes plasma membrane to bleb out from the cell, 
leading to EV formation. F: EVs form as a result of explosive cell lysis or “bubbling” cell death. LPS: 





Mechanism how gram-positive bacteria release BMVs despite the thick 
peptidoglycan cell wall have been suggested to involve degradation of peptidoglycans that 
allows the release of BMVs (Liu et al., 2018). It was demonstrated that the expression of 
prophage-encoded endolysin in Bacillus subtilis caused holes in the cell wall, which allowed 
plasma membrane to bleb out from the bacterial cell. BMV production also induced vesiculation 
from adjacent bacterial cells. However, BMV production was shown to be lethal for the 
bacterial cells (Toyofuku et al., 2017). Prophage-independent BMV production mechanism is 
suggested to involve phenol-soluble modulins (a family of surfactant-like proteins) and 
peptidoglycan cross-linking that resulted BMV production from Staphylococcus aureus (Wang 
et al., 2018). 
EVs are resistant to proteases (Kesty & Kuehn, 2004). Therefore, they can 
transport otherwise protease-susceptible molecules to further destinations than these cargo 
molecules would travel without protecting membrane. Packing cargo in EVs could ensure that 
proteins are delivered in high concentrations to distant targets where high effector concentration 
is required to achieve an effect (Kulp & Kuehn, 2010). Indeed, bacterial EVs have been shown 
to recognize different bacterial cells and harbor specificity for their targets (Toyofuku et al., 
2017). 
In bacteria-bacteria interaction, EVs can contain signal molecules, which are used 
to communicate and coordinate social activities between bacterial cells (Mashburn & Whiteley, 
2005), known as quorum sensing (Parsek & Greenberg, 2000). Bacterial EVs can fuse to other 
bacteria and release their cargo, including proteins (Vasilyeva et al., 2008) and genetic material 
into recipient cells (Kahn et al., 1983; Kolling & Matthews, 1999; Renelli et al., 2004; Yaron 
et al., 2000). EV fusion can provide a repertory of foreign antigens, that recipient bacteria can 
represent on their outer membrane (Kadurugamuwa & Beveridge, 1996; Kadurugamuwa & 
Beveridge, 1999). EVs have shown to traffic phage receptors to otherwise resistant bacterial 
cells and make them susceptible for phage infection (Tzipilevich et al., 2017). Bacteria can 
pack misfolded proteins and toxic compounds and remove them via, vesiculation that increases 
bacterial survival (McBroom & Kuehn, 2007). EVs are also capable to bind (Schooling & 
Beveridge, 2006) and degrade (Ciofu et al., 2000) antibiotics to prevent antimicrobial action. 
2.7 Pathogenic and beneficial properties of microbial extracellular vesicles 
Microbial EVs are thought to be potential pathogenic factors due to their capability to carry 




& Kuehn, 2010). Studies regarding EVs of potentially harmful bacteria have shown that EVs 
contribute to pathogenic actions. Staphylococcus aureus, a common opportunistic pathogen, 
releases EVs that contain several toxins, such as α-hemolysin, δ-hemolysin, γ-hemolysin, 
leukotoxin D, exfoliative toxin C, and exfoliative toxin A. (Gurung et al., 2011; Jeon et al., 
2016; Thay et al., 2013). S. aureus EVs are cytotoxic (Gurung et al., 2011; Thay et al., 2013) 
and promote inflammation when inhaled (Kim et al., 2012). Escherichia coli EVs are capable 
to lyse red blood cells (Balsalobre et al., 2006) and induce systemic inflammatory response 
syndrome or lethal sepsis (Park et al., 2010). EVs from certain strains of E. coli contain heat-
labile enterotoxin (Wai et al., 1995), that is known to cause diarrhea (Spangler. 1992). 
Enterotoxigenic E. coli EVs were able to target and release enterotoxin into host adrenal gland 
and intestinal epithelial cells, whereas EVs from non-pathogenic strain didn’t show cell 
specificity (Kesty et al., 2004). EVs from different E .coli strains cause distinct immunological 
responses, meaning that host responses to microbial EVs are strain specific (Diaz-Garrido et 
al., 2019). 
Interestingly, EVs can promote the growth of pathogenic bacteria. Such is case 
with Mycobacterium tuberculosis, which was shown to proliferate faster in lungs and spleens 
of mice that were injected with M. tuberculosis EVs beforehand (Prados-Rosales et al., 2011). 
M. tuberculosis EVs induced T cell anergy, which was suggested to be caused by EV delivered 
lipoarabinomannan, a phagosome maturation inhibitor present in mycobacterial membrane 
(Athman et al., 2017). 
As with beneficial bacteria, EVs can also have favorable properties. Lactobacillus 
casei EVs were found to contain P40 and P75 hydrolases (Rubio et al., 2017), proteins that 
have been associated with intestinal cell proliferation and survival (Yan et al., 2007). EVs of 
Bifidobacterium longum were able to alleviate food allergy symptoms in mice by inducing mast 
cell apoptosis, and reduce the occurrence of diarrhea in dose-dependent manner (Kim et al., 
2016). EVs from Lactobacillus rhamnosus GG were reported to have anti-proliferative effect 
on liver cancer cells (Behzadi et al., 2017), and Lactobacillus plantarum WCFS1 EVs were 
able to increase Caenorhabditis elegans survival against vancomycin-resistant Enterococcus 
faecium infection (Li et al., 2017). 
EVs derived from vaginal Lactobacillus were reported to protect human T cells, 
cervico-vaginal and tonsillar tissues from HIV-1 replication and inhibit viral attachment as well 




Bacteroides fragilis, bacteria, that produce PSA with anti-inflammatory properties, have shown 
to release PSA containing EVs. B. fragilis EVs were able to protect mice from experimental 
colitis by suppressing TNF-α production and Th-17 development. PSA is recognized by DCs 
via TLR2 dependent manner, thus enhancing Tregs and production of anti-inflammatory 
cytokines (Shen et al., 2012). 
Akkermansia muciniphila EVs were also shown to reduce the severity of 
experimental colitis in mice (Kang et al., 2013). A. muciniphila EVs, when administered to 
mice with high-fat diet,  decreased the permeability of gut tight junctions, reduced weight gain 
and improved glucose tolerance (Chelakkot et al., 2018). Beneficial impact on reduced weight 
gain of A. muciniphila EVs was shown to be greater compared to actual bacterial cells 
(Ashrafian et al., 2019). Intestinal barrier reinforcing function (Alvarez et al., 2016) and 
ameliorating effect in experimental colitis (Fábrega et al., 2017) have also been observed with 
E. coli Nissle 1917 EVs. 
Interesting about bacterial EVs in the gut is, that EVs have been shown to cross 
intestinal epithelium, enter host circulation, locate to organs (Jones et al., 2020), and cross BBB 
to CNS (Wei et al., 2020). Gut microbiota are suggested to contribute to brain development, 
behavior, and neurodegenerative diseases (Cryan & Dinan, 2012; Forsythe et al., 2012; Foster 
et al., 2016; Sarkar & Banerjee, 2019) but the mechanisms behind these actions are largely 
unknown. Few recent studies have reported that microbial EVs potentially affect brain function 
and behavior. One study reported that administration of gut microbiota derived EVs from 
Alzheimer’s disease patients induced neuroinflammation, tau protein hyperphosphorylation, 
and cognitive impairment in mice (Wei et al., 2020). Another study showed that EVs of L. 
plantarum affected the expression of neurotropic factors in mouse hippocampus and had anti-





II EXPERIMENTAL PART 
3. Aim of the project 
Aim of the project was to determine, whether gut-microbiota-derived EVs from fecal samples 
are different between MS patients and healthy controls. Our hypothesis is that EVs produced 
by the gut microbiota are a major host-modulating factor in health and disease, including MS. 
According to our knowledge, no literature has been published regarding the role of gut 
microbial EVs in MS. 
4. Materials and Methods 
4.1 Samples 
Fecal samples from sixteen (16) recently diagnosed MS patients (< 5 years from diagnosis) and 
18 healthy controls were kindly provided by Prof. Anne Remes. Both sample groups 
represented mixed sex and age. Two in-house healthy control fecal samples were used to verify 
EV isolation protocol suitability. All samples were stored at -80 C° prior use. 1x modified 
Dulbecco’s phosphate buffered saline (DPBS) was used as a negative control. 
4.2 Isolation of extracellular vesicles 




Figure 6. Experimental workflow. EVs were isolated and purified from fecal material (steps 1 - 4). Isolated EVs 
were qualified with transmission electron microscopy (TEM) and nanoparticle tracking analysis (NTA) (step 5). 
Proteins were isolated from EVs (step 6). Isolated proteins were analyzed by using liquid chromatography-
electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS), PEAKS bioinformatics software, and in-
house developed bioinformatics tools (steps 7 - 8).  
 
4.2.1 Filtration 
100-1000 mg of thawed fecal material was suspended in sterile-filtered 1x DPBS (Sigma-
Aldrich). Suspended samples were centrifuged at 14 000 g for 30 min at +4 C° with a fixed 
angle rotor. Supernatant was collected and centrifuged again. After centrifugation, supernatant 
was filtered with 40 µm nylon filter (Falcon Cell strainer) and sterile-filtered with 0,45 µm 
PES-filter (Biofil 1000ml Vacuum bottle filter). Filtered samples were stored at +4 C° Same 
0,45 µm PES-filters were used to prepare all other sterile-filtered solutions. 
4.2.2 Concentration 
Filtered samples were concentrated by using Centricon® Plus-70 PL-100 centrifugal filter 
devices (Merck Millipore) according to manufacturer’s manual. Due to lack of suitable rotor 




were washed with sterile-filtered 1x DPBS by centrifugation with a swinging bucket rotor at 
3500 g for 5 min at +4 C° and liquid left in filters was removed by centrifugation at 1000 g for 
2 min at +4 C°. Samples were concentrated by centrifugation at 3500 g for 45 min at +4 C°. 
Concentrated samples were retrieved by centrifugation at 1000 g for 2 min at +4 C°. Samples 
were stored at +4 C°. 
4.2.3 Size exclusion chromatography 
EVs (30-300 nm in diameter) were isolated from concentrated samples by using Exo-SpinTM 
Mini-Columns (Cell guidance systems). Storage liquid in the column was removed by spinning 
at 50 g for 10 sec with a swinging bucket rotor. The column was washed with sterile-filtered 1x 
DPBS by spinning at 50 g for 10 sec. Sample was added to the column and spinned at 50 g for 
1 min. EVs were eluted from the column by adding sterile-filtered 1 x DPBS and by spinning 
at 50 g for 1 min. Isolated EVs were stored at 4 °C. 
4.2.4 Density gradient ultracentrifugation 
EVs were purified by using OptiPrepTM density gradient ultracentrifugation. Gradient solutions 
were done by using sterile-filtered homogenization medium (HM; 0,25M Sucrose, 10mM Tris-
HCl, 1mM EDTA, pH 7,4) and sterile-filtered working solution buffer (WSB; 0.25M Sucrose, 
60mM Tris-HCl, 6mM EDTA, pH 7,4). Working solution (WS) was done by mixing 
OptiprepTM gradient media (60% w/v iodixanol in water) and WSB in 1:5 ratio. 40%, 20%, 
10%, and 5% OptiPrepTM gradient solutions were freshly prepared by mixing WS and HM. 
Density gradient was prepared by adjusting 40 %, 20 %, 10 %, and 5% solutions, respectively, 
into ultracentrifugation tubes (14 x 89 mm  Ultra-Clear, Beckman Coulter). Sample was put on 
the top of the gradient and centrifuged at 100 000 g ≥ 15 hours at 4C° with a swinging bucket 
rotor. After centrifugation, gradient-sample mixture was divided into 10 fractions. Sample 
fractions were stored at +4 °C. 
4.2.5 Washing of extracellular vesicles 
Frequently, fractions 5-7 included purest and highest amount of EVs. EVs appeared in fractions 
4 and 8 as well. However, fraction 4 was usually empty and fraction 8 had often excess amount 
of impurities, as analyzed by TEM. To save time, fractions 5-7 were usually selected for 
washing. Fractions were mixed with sterile-filtered 1x DPBS and washed by ultracentrifugation 
at 100 000 g for 2,5 hours at 4 °C. 14 x 89 mm Polypropylene Centrifugation Tubes (Beckman 
Coulter) were used for sample washing. Supernatant was removed and the pellet was suspended 




4.3 Qualification of extracellular vesicles 
4.3.1 Negative staining 
Negative staining was performed by the Biocenter Oulu electron microscopy core facility 
service. Washed EV fractions were negatively stained. Drop of EV sample was placed on 
carbon coated glow-discharged copper grid (400 mesh). Sample was incubated on the grid for 
20 min. Grids were washed twice with a drop of PBS for 1 min. Samples were fixed with 1 % 
glutaraldehyde in PBS for 5 min. Grids were washed 8x1 min in a drop of water, stained with 
neutral 2 % uranyl acetate (UA), washed again with water, and coated with a droplet of 2 % 
methylcellulose-UA for 10 min. Grids were removed from the droplet and excess fluid was 
blotted with Whatman no. 1 filter paper. Grids were dried ≥10 min and stored in a grid storage 
box at RT. 
4.3.2 Transmission electron microscopy 
Transmission electron microscopy (TEM) was used to check the purity and presence of EVs in 
samples by using Tecnai G2 Spirit microscope. Since EVs tend to accumulate on the edge of 
the grid due to one-sided blotting, the grids were imaged in a five-point manner, starting from 
the middle and moving through four corners in square-shaped form. Images were taken with 
23 000x or 18 500x magnification. 
4.3.3 Fraction combination 
Fractions of the same sample, which were considered to have pure EVs, were combined. 
Fractions selected for combination had clearly less amount of non-EV material (flagella and 
fibrils) compared to the amount of EVs present in the sample. Combined fractions were stored 
at 4 °C. 
4.3.4 Nanoparticle tracking analysis 
EV concentration and size distribution was determined with nanoparticle tracking analysis 
(NTA). Used NTA instrument was NanoSight NS300 (Malvern) coupled with NanoSight NTA 
Software. NS300 is a laser-based light scattering system that illuminates and tracks nanosized 
particles (10-2000 nm in diameter). According to manufacturer’s manual, accuracy of NS300 
is at highest when measured particle concentrations are between 107-109 particles/ml. 
Therefore, EV sample aliquots were diluted in sterile-filtered 1x DPBS to ensure good 
reliability. Used mixture ratio was 1:24. EVs from one sample were measured with 4 
consecutive 1 min long imaging sessions and results from each measurement were combined. 




4.4 Protein analysis of extracellular vesicles 
4.4.1 Methanol precipitation of extracellular proteins 
Extracellular proteins were precipitated by mixing sterile water, methanol, and chloroform to 
washed samples. Samples were vortexed and centrifuged at 14 000 g for 1 min by using a fixed 
angle rotor. Methanol-water-mix and chloroform formed a layer where precipitated proteins 
located. Methanol-water mix was removed from the top of the interface. Protein precipitate was 
washed by adding more methanol. Samples were vortexed and centrifuged at 16 000 g for 5 
min to pellet precipitated proteins. Supernatant was removed and pellets were dried until no 
liquid was seen in the tubes. Samples were suspended in 1x Laemly loading buffer, boiled at 
95 °C for 5 min, and cooled. 
4.4.2 Protein loading 
Precipitated protein samples were loaded on pre-casted 12 % separating gels (Mini-Protean 
TGX, Bio-Rad) and run at 10-15 min at 110 V until the Laemly loading buffer had moved ~1 
cm. Gel run was performed to store precipitated proteins in the gel. The gel was fixed in 50 % 
ethanol and 10 % acetic acid for 30 min in a shaker at RT and rinsed with sterile water. The gel 
was stained with 1x Sypro Ruby protein stain in a shaker for overnight at RT. The gel was de-
stained with 5 % acetic acid for 5 min in a shaker. ~1 x 1cm gel pieces, that contained sample, 
were cut under the UV light with a scalpel. Gel pieces were dried with absolute ethanol by 2 x 
5 min incubation at RT until the gel pieces became white and hard. Ethanol was removed and 
dried gels were stored at -20 °C. 
4.4.3 Sample submission 
Dried gels were sent at ambient temperature to Turku Bioscience Proteomics Facility for protein 
identification analysis. 
4.4.4 Reduction 
Samples were processed at Turku Bioscience Proteomics Facility according to their standard 
protocols. Dried gels were rehydrated and washed 3 x 10 min with water. Proteins present in 
gels were reduced with 20 mM 1,4-dithiotreitol for 30 min. Gels were dehydrated with 100 % 
acetonitrile (ACN). 
4.4.5 Alkylation 
Gels were alkylated with 55mM iodoacetamide for 20 min in dark at RT and washed twice with 
100 mM ammonium bicarbonate. Gels were dehydrated with ACN and dried with vacuum 




4.4.6 Trypsin digestion 
Gels were digested with 0,02 µg/µl trypsin solution for 20 min. Gels were covered with 10% 
ammonium bicarbonate solution and incubated overnight at 37 °C. 
4.4.7 Extraction of peptides 
100% ACN was added to samples. Samples were vortexed and incubated for 15 min at 37 °C. 
Supernatant was collected. Extraction was repeated with 50 % ACN/5 % formic acid solution. 
Solution was dried with vacuum centrifugation. Dried samples were stored at -20 °C. 
4.4.8 Liquid chromatography-electrospray ionization-tandem mass spectrometry 
For mass spectrometry, samples were suspended in formic acid. Liquid chromatography-
electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) analysis was done with 
nanoflow HPLC system (Easy-nLC1200, Thermo Fisher Scientific) and coupled with Q 
Exactive HF mass spectrometer (Thermo Fisher Scientific). Mass spectrometer was equipped 
with a nano-electrospray ionization source. Samples were loaded on a trapping column and 
separated on a 15 cm C18 column (75µm x 15 cm, ReproSil-Pur 5µm 200 Å C18-AQ, Dr. 
Maisch HPLC GmbH). The mobile phase included water with 0,1 % formic acid (solvent A) 
and ACN/water (80:20 v/v) with 0,1 % formic acid (solvent B). Peptides were eluted with linear 
gradient (8 % to 43 %) of solution B for 10 min. Data was received by using Thermo Xcalibur 
4.1 software (Thermo Fisher Scientific). 
4.4.9 PEAKS analysis 
Raw proteomics data from LC-ESI-MS/MS was provided by Turku Bioscience Proteomics 
Facility. Raw data was processed with PEAKS software (Bioinformatics Solutions Inc.). 
PEAKS software was used to identify peptides/proteins of a protein mixture based on database 
and spectral library searching and de novo sequencing. 
4.4.10 Protein analysis 
 Protein content analysis of MS patient and healthy control EVs was performed with in-house 
developed bioinformatic algorithm based on R tool. 
5. Results 
5.1 Sufficient isolation of extracellular vesicles was possible with ≤1000 mg of fecal 
material 
In the original protocol 4000 mg of fecal material was used for isolation. However, provided 




with variable amount of fecal starting material from reserve control samples. First EV isolation 
test was done with 100, 200, 400, 600, 800, and 1000 mg of fecal material from the same fecal 
sample. First isolation round included EV isolation, EV quantification, methanol precipitation 
of extracellular proteins and protein loading to gel. EV isolation test was repeated with another 
control fecal sample using 100, 200, 400, and 600 mg of fecal starting material. Methanol 
precipitation of extracellular proteins and protein loading to gel were excluded from the second 
test since point of interest was to verify the presence of EVs. 
EVs were isolated from both test samples and fractions 5-8 were selected for 
washing. Fractions were negatively stained according to the described protocol and imaged 
with TEM. TEM showed that EVs were present in all tested samples (Fig. 7. and Fig. 8.). 
Observed EVs varied by their structure and size (Fig. 9.). Part of the EVs showed wrinkled, 
round or tube-like structure. Surface of the EVs appeared smooth, granular or fibrous. EVs 
sometimes formed aggregates where multiple EVs are stuck together. EVs that resembled 
multilamellar bodies were also present in samples. Flagella-like structures were common in 
fraction 8. Therefore, fraction 8 from all samples were excluded from the NTA analysis. 
Fractions 5-7 per sample were combined. EV concentration of the samples were 
measured with NTA (Fig. 10.) and compared to results from 4000 mg of fecal material (Check 
attachments, Supplement Fig. 1). Magnitude of EV concentration per ml increased along with 
the amount of used fecal material and varied between the 9th power and 10th power.  
Proteins from the first test sample were isolated and loaded into a gel (Fig. 11.). 
The gel was imaged and cut under the UV light. Three bands were visible in the gel 
corresponding to 600, 800 and 1000 mg of fecal starting material. The well corresponding to 
400 mg sample looked shady but due to image background it was difficult to interpret. 
Overall, presented data showed that EV isolation was reasonable with smaller 




Figure 7. Transmission electron microscopy results of EVs isolated with variable amount of fecal material from 
the first test sample. EVs showed variation in size and structure. Purity and quantity of EVs was usually highest 
in fractions 5-7 (data not shown). EVs appeared with a single bilayer or with a double bilayered structure. 
Magnification 23 000x. A: 100 mg of fecal material, fraction 7. B: 200 mg of fecal material, fraction 7. C: 400 mg 
of fecal material, fraction 5. D: 600 mg of fecal material, fraction 7. E: 800 mg of fecal material, fraction 6. F: 







Figure 8. Transmission electron microscopy results of EVs isolated with variable amount of fecal material from 
the second test sample. Magnification 23 000x. A: 100 mg of fecal material, fraction 6. B: 200 mg of fecal material, 





Figure 9. TEM images of different EV-like particles and other structures present in samples. 23000 x 
magnification. A: Flagella-like structures are often present in fraction 8. B: Collation of EV-like structures. Upper 
left; EV-particle with fibrous-like surface. Upper right; wrinkled EV-particle. Lower left; tube-shaped EV particle. 






Figure 10. Logarithmic EV concentrations per ml (Y-axis) of test samples. NTA was used to determine EV 
concentration. Variable amount of fecal material (X-axis) was used for EV isolation. A: EV concentrations of the 
first test sample. B: EV concentrations of the second test sample.  
 
 
Figure 11. Isolated proteins of the first test sample in a gel. Three bands corresponding to 600, 800 and 1000 mg 
of fecal material used were visible in the gel. 
 
5.2 Extracellular vesicles were similar in size and concentration between multiple sclerosis 
patients and healthy controls 
EVs were isolated from MS disease and healthy control fecal samples by using 400 mg of fecal 
material. Fractions 5-7 were washed, negatively stained and imaged with TEM. Unfortunately, 
coating of grids was thicker than usual due to evaporation of the coating stock solution. Thick 
coating made samples more difficult to image and interpret (Fig. 11). Quantity of EVs in TEM 
samples varied from abundant to almost empty. 






























Fractions 5-7 were combined from each sample and measured with NTA. In MS 
group mean concentration of EVs was 1,14E+10 ±8,59x109 particles/ml, whereas EV 
concentration in healthy controls was 6,51x109 ±5,52x109 particles/ml. Differences in 
concentration did not reach statistical significance (Fig. 14.). Distribution of EVs by 
concentration and size varied in both groups (Fig. 12. & 13.) where majority of EVs were either 
centered or dispersed along X-axis. Mean size of EVs in MS group was 202,0±31,8 nm and 
modal average was 162,3±22,9 nm. Mean EV size in healthy controls was 191,3±27,4 nm and 
modal average 153,1±26,1 nm. Distribution of EVs was evaluated with D10, D50 and D90 
values, which represents a threshold value where a certain percentage of EVs (10%, 50% or 
90%) are smaller than the given threshold size. For MS group mean D10, D50 and D90 were 
132,8±15,6 nm, 184,4±28,3 nm, and 291,8±55,1 nm, respectively. For healthy controls 
distribution values in respected order were 122,9±17,2 nm, 173,5±25,9 nm and 280,7±50,7 nm. 
While mean, modal averages, and mean values of D10, D50 and D90 were higher in MS group 
compared to healthy controls, the results weren’t statistically significant. Overall, results 
suggest that size and concentration of EVs were similar between groups. 
Proteins were isolated from EV samples of both groups and loaded into gels (Fig. 
15.) where few bands were visible under the UV light. Gel pieces were cut from the gel, dried 
with ethanol, and send to Turku Bioscience proteomics facility for protein sequencing. Samples 
were analyzed with LC-ESI-MS/MS and raw data from the measurement was received for 
protein identification and analysis. Unfortunately, acquiring results from protein analysis was 
delayed due to hinderances caused by the SARS-CoV-2 procedures during spring 2020. 





Figure 11. TEM image examples of isolated EVs from MS patients and healthy controls. Amount of EVs present 
in TEM samples varied between samples in both sample groups. A: MS patient sample, fraction 5, 18500x 
magnification. Thick coating made samples difficult to see through. Electron beam was centered on a smaller area 
to visualize EVs. B: MS patient sample, fraction 7, 23000x magnification. C: Healthy control EVs with few fibril-






Figure 12. Disperse (left column) and centered (right column) EV distribution examples from MS patients. EV 
concentration and size was measured with NTA. Y-axis: concentration (particles / ml). X-axis: Size (nm). Black 






Figure 13. Disperse (left column) and centered (right column) EV distribution examples from healthy controls. EV 
concentration and size was measured with NTA. Y-axis: concentration (particles / ml). X-axis: Size (nm). Black 
















Figure 14. Comparison of EV concentration and size between MS patients and healthy controls. A: EV 
concentration (particles / ml) of MS patients and healthy controls. B-D: D10, D50 and D90 size distribution of 
EVs between MS patients and healthy controls. D10, D50 and D90 describes the EV size where 10 %, 50%, and 
90 % of vesicles are smaller than the threshold value (Y-axis). E: Mean EV size of MS patients and healthy 
controls. F: Mode EV size of MS patients and healthy controls. nm: nanometer. 
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Figure 15. Gel picture of proteins isolated from MS patients and healthy control EVs. MS: MS patients. HC: 








EVs produced by the gut microbiota offer an intriguing mechanism how the gut microbiota can 
alter host function. Role of gut microbiota derived EVs is a novel field of research and largely 
unknown factor regarding host-microbiota interaction in health and disease. This work aimed 
to study microbial EVs isolated from fecal samples of MS patients and healthy controls, and 
according to our knowledge, is the first time such analysis was done with MS samples. 
Provided fecal samples for the experimental work were smaller than anticipated. 
Therefore, suitability of samples for EV isolation was tested with in-house fecal control samples 
that were 100-1000 mg in weight. EVs were successfully isolated from all tested samples. Using 
smaller amount of fecal material also prevented clogging of used filters and concentrators, 
which was a frequent problem when 4000 mg of fecal material was used. Smaller sample size 
for future EV isolations could provide practical benefit, regarding space limitations in sample 
storage and use of equipment, as less amount of plastics and reagents are required for isolation, 
potentially making EV isolation from fecal samples faster and more affordable. 
Concentration and size of isolated EVs were similar between sample groups while 
great variation was observed between individuals. NTA graphs showed that EV populations 
were either centered between certain size range, seen as single peak, or distributed with multiple 
peaks, possibly representing subgroups within EV population. The gut microbiota composition 
have been observed to be similar in phylum level among humans, but similar to fingerprints, 
the gut microbiota composition of each individual is unique (Lozupone et al., 2012; Quigley. 
2013), which is probably also interlinked to EV profile.  Indeed, next objectives are to 
recognize, which bacteria release the most of EVs based on EV 16S sequencing, determine gut 
microbiota composition from whole fecal sample, and compare results to known gut 
microbiome data regarding MS disease and healthy controls. 
Even though size exclusion chromatography was used to collect EVs that were 
30-300 nm in diameter, particles larger than 300 nm were recorded in NTA. This could be 
explained by the formation of EV aggregates seen in TEM images. Formation of EV aggregates 
presumably occurs during density gradient ultracentrifugation and sample washing, since 
centrifugation at 100 000 g has been shown to generate EV aggregates (Linares et al., 2015), 
which can potentially affect concentration and biological properties of EVs. 
Despite collected EVs were within bacterial vesiculation range, isolated EVs 




including the host and ingested food. Currently, microbial EVs cannot be separated from EVs 
of other source. Mixed EV population does not impede protein analysis since identification of 
proteins from other sources can be excluded from the analysis. However, multi-source nature 
of EV population should not be ignored when assessing the role of microbial EVs if functional 
experiments are performed with feces derived EVs. 
Since EVs were isolated based on their size and density, virions with similar 
properties may also be present in samples (Momen-Heravi et al., 2013). Careful interpretation 
of TEM images is required as spherical shaped virions can be mistaken for EVs, potentially 
causing false positive observations. However, distinguishing EVs from virions can be 
challenging due to variation in the appearance of bacterial EVs, which can e.g. appear smooth 
or granular (Dorward et al., 1989). Consequently, presence of virions can cause bias in NTA 
analysis regarding EV concentration and size distribution but evaluating the impact of virions 
in EV characterization is currently inaccessible. 
Another problem is uncertainties in EV preservation. Proteins from MS samples 
and few control samples were isolated before closing of the university due to SARS-CoV-2 
pandemics. Proteins from the rest of the control samples were isolated two months later. For 
the whole time EVs were kept at 4 °C, which could potentially affect EV properties. Regarding 
proteins however, stability of enzymatic activity is preserved in EVs better compared to free 
enzyme over wide scale of temperatures ranging from -80 to 37 °C. It was reported that ~80 % 
enzyme activity was maintained when EVs were stored for 14 days at 4 °C or at -80 °C (Alves 
et al., 2016), suggesting that EVs provide a microenvironment that is favorable for protein 
preservation. On the other hand, long-term preservation of RNA in EVs is suggested to require 
-80 °C storage conditions (Mendt et al., 2018).  
Amount of isolated protein, based on visual interpretation of gels, varied between 
samples in both groups. Sadly, results of protein analysis were excluded from this work due to 
unfortunate global situation. Originally, protein data was scheduled to be ready latest at 2020 
spring. However, practical work halted during early spring for two months due to closing of the 
university of Oulu as an attempt to slow down the spreading of SARS-CoV-2. Experimental 
work continued after re-opening of the university and protein samples were sent in June 2020 
to Turku Bioscience proteomics facility for protein sequencing. Analysis of protein data 
required a bioinformatics specialist who had a scheduled vacation at the time, and subsequently, 




 As previously described studies indicate that colonization of mice with MS 
patient microbiota changes the course of EAE, it would be interesting to test whether the 
administration of feces-derived EVs from MS patients affects EAE severity, population of 
immune cells and cytokine profile. Practically, role of EVs in MS could be observed by 
repeating similar experimental settings what were used in previously discussed studies 
regarding the role of gut microbiota in EAE.  
7. Conclusions 
Studying gut microbiota derived EVs is a thrilling but challenging field of research, partly due 
to its novel nature. The role of gut microbiota in health and disease has received sky-rocketing 
interest and certainly increased attention regarding the role of gut microbial EVs will follow. 
This work aimed to study gut microbial derived EVs from MS patients and healthy controls. 
Size and concentration of EVs were statistically similar between groups while all mean values 
were higher in MS group compared to healthy controls. This work failed to represent the main 
objective, which was the protein content analysis of gut microbiota derived EVs in MS patients 
and healthy controls. However, this work accomplished to show that sample size as low as 100 
mg is enough for EV isolation, which can be used to improve EV isolation practice.  
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9. Attachments 
Supplement figure 1. EV concentration in logarithmic scale of the first test sample combined with previously 
observed EV concentration with 4000 mg of fecal starting material. A: Concentrations of the first test sample 
combined with 4000 mg data from other measurement. Concentration of the 4000 mg sample is not totally 
comparable since 2,5x volume of EV eluant from Exo-Spin EV isolation step was used in density gradient 
ultracentrifugation compared to other samples. B: Concentrations of the second test sample combined with 4000 
mg data from other measurement. Concentration of the 4000 mg sample is not totally comparable due to 
uncertainties in the used volume (either 1-2,5x) of EV eluant from Exo-Spin EV isolation step compared to other 
samples. 
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